NXC-201 not checked
Nexcella Inc. · HBI0101 CAR-T
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NXC-201 CAR-T is defined as autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector encoding a proprietary chimeric antigen receptor (CAR) targeted to human BCMA.”In the company’s words, NCT07709715 on ClinicalTrials.gov
- Tested for
- Light Chain (AL) Amyloidosis (2 trials)
- Main trialPhase 3
- “The purpose of this study is to evaluate the efficacy and safety of NXC-201 compared with Dara-CyBorD (daratumumab-cyclophosphamide-bortezomib-dexamethasone) in the treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.”In the company’s words, NCT07709715 on ClinicalTrials.gov
- Other names
- HBI0101 CAR-T
Other drugs for Light Chain (AL) Amyloidosis
- NTLA-2001Intellia Therapeutics · Phase 3
- ALXN2220Alexion Pharmaceuticals, Inc. · Phase 3
- NucresiranAlnylam · Phase 3
- VutrisiranAlnylam · Phase 3
- SCTC21CSinocelltech · Phase 3
- EtentamigAbbVie · Phase 3
Coming up2
- DecPhase 1/2 trial completes · ClinicalTrials.gov
- Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Dec 2028 | A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis | |
| Phase 1/2Active, not recruiting | Dec 2026 | Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026